Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

By K. Flaherty, I. Puzanov, Kevin B. Kim, Antoni Ribas, G. McArthur, J. Sosman, P. O'dwyer, Richard J Lee, J. Grippo, K. Nolop and 1 more. New England Journal of Medicine, 2010

3,615 citations recorded by the source corpus.

Background The identification of somatic mutations in the gene encoding the serine–threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease. Methods We conducted a multicenter, phase 1, dose-escalation trial of PLX4032 (also known as RG7204), an orally available inhibitor of mutated BRAF, followed by an extension phase involving the maximum dose that could be administered without adverse effects (the recommended phase 2 dose). Patients received PLX4032 twice daily until they had disease progression. Pharmacokinetic analysis and tumor-response assessments were conducted in all patients. In selected patients, tumor biopsy was performed before and during treatment to validate BRAF inhibition. Results A total of 55 patients (49 of whom had melanoma) were enrolled in the dose-escalation phase, and 32 additional patients with metastatic melanoma who had BRAF with the V600E mutation were enrolled in the extension phase. The recommended phase 2 dose was 960 mg twice daily, with increases in the dose limited by grade 2 or 3 rash, fatigue, and arthralgia. In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BRAF mutation and who were receiving 240 mg or more of PLX4032 twice daily, 10 had a partial response and 1 had a complete response. Among the 32 patients in the extension cohort, 24 had a partial response and 2 had a complete response. The estimated median progression-free survival among all patients was more than 7 months. Conclusions Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients. (Funded by Plexxikon and Roche Pharmaceuticals.)

Subfields: Hematology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/86665a3d2c3b839dd66711b7ed9d1bc282a39531

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

  1. Levi A. Garraway
  2. Florent Ginhoux
  3. P. Jänne
  4. J. Settleman

In Molecular Biology

  1. Shankar Balasubramanian
  2. S. Rosenberg
  3. Stephen Neidle
  4. Myles A. Brown
  5. X. S. Liu
  6. N. Restifo
  7. M. Dudley
  8. L. Hurley

In Oncology

  1. S. Rosenberg
  2. N. Restifo
  3. M. Dudley
  4. Jie Yang
  5. Jordi Bruix1 , 2
  6. J. Engelman
  7. P. Jänne
  8. R. Sherry

Citations in the corpus